A randomized controlled trial of colistin combined with sulbactam: 9 g per day versus 12 g per day in the treatment of extensively drug-resistant resistant Acinetobacter baumannii pneumonia
Phase 4
Completed
- Conditions
- Extensively drug resistance Acinetobacter baumannii pneumoniaXDR A. baumannii, colistin, high dose sulbactam
- Registration Number
- TCTR20190623002
- Lead Sponsor
- Department of Medicine, Phramongkutklao Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 138
Inclusion Criteria
A. baumannii XDR pneumonia patients
-Age 18 or over 18 years old
Exclusion Criteria
-Sputum culture shows mixed organisms
-Concurrent or coinfection with other organs
-Not received colistin for empirical treatment
-Receive colistin >6 calendar days before date of collected sputum
-Allergy to colistin or sulbactam
-Previous participated in this trial within 14 days
-Pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method mortality 7 and 28 days mortality rate
- Secondary Outcome Measures
Name Time Method ICU day, ventilator day, adverse event until discharge from ICU, off mechanical ventilator, complete treatment length of ICU stay or mechanical ventilator use, adverse drug events,Factor associated mortality 28 days mortality